Arrhythmias & electrophysiologySecondary analysis
Anticoagulation with edoxaban in patients with long atrial high-rate episodes ≥24 h
- Secondary analysis of the NOAH-AFNET 6 randomised trial
- pre-specified
Authors' conclusion
This hypothesis-generating analysis does not find an interaction between AHRE duration and anticoagulation therapy in patients with device-detected AHRE and stroke risk factors.
Study context
- Population
- Patients with device-detected AHRE and stroke risk factors; subgroup with AHRE ≥24 h259 with AHRE ≥24 h
- Participants
- 2,389 patients
- Comparison
- Edoxaban vs placebo, by AHRE duration
- Primary endpoint
- Stroke, systemic embolism or CV death; interaction with AHRE duration
- Follow-up
- Median 1.8 years
Primary result
As reported in the abstract
Primary outcome in AHRE ≥24 h (subgroup)
| Group | n | Value | Strokes |
|---|---|---|---|
| Edoxaban | 132 | 4.3%/patient-year | 2 |
| Placebo | 127 | 6.9%/patient-year | 2 |
- AHRE duration did not interact with efficacy of anticoagulation
- P for interaction = 0.65
Secondary outcomes
| Outcome | AHRE ≥24 h | Shorter AHRE | P value |
|---|---|---|---|
| ECG-diagnosed AF, AHRE ≥24 h vs shorter AHRE | 17.0%/patient-year | 8.2%/patient-year | P < 0.001 |
Major bleeding and death
- AHRE duration did not interact with safety of anticoagulation
- P for interaction = 0.98
- interaction P-interaction = .98
Original publication
Anticoagulation with edoxaban in patients with long atrial high-rate episodes ≥24 h. Eur Heart J. Published 12 November 2023. doi:10.1093/eurheartj/ehad771
Summarised from the published abstract; every number is checked against it